Latest Ratios: P/E Ratio -1.0x · EV/EBITDA N/A · ROE -51.8%. (2011–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $122M | $117M | $188M | $368M | $977M | $5.5B | $7.5B | $1.3B | $721M | $257M | $80M |
| Enterprise Value | $154M | $148M | $237M | $430M | $1.0B | $5.5B | $7.4B | $1.3B | $545M | $182M | $2M |
| P/E Ratio → | -1.04 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 25.77 | 17.56 | 13.76 | 5.79 | 10.15 | 99.27 | 238.32 | 124.95 | 152.11 | 62.47 | 18.11 |
| P/B Ratio | 0.60 | 0.56 | 0.59 | 1.00 | 2.02 | 8.17 | 19.49 | 5.45 | 4.49 | 3.32 | 1.09 |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 22.26 | 17.37 | 6.76 | 10.64 | 98.93 | 236.09 | 118.13 | 115.05 | 44.41 | 0.40 |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | -94.1% | -94.1% | -769.6% | -147.4% | 85.7% | 89.5% | -299.6% | 100.0% | -1081.9% | -736.8% | -500.9% |
| Operating Margin | -2222.4% | -2222.4% | -1542.6% | -299.9% | -320.2% | -388.6% | -407.5% | -943.1% | -1415.4% | -1025.9% | -726.1% |
| Net Profit Margin | -2051.1% | -2051.1% | -1366.5% | -253.3% | -292.5% | -379.9% | -551.6% | -919.0% | -1405.0% | -1046.1% | -760.2% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -51.8% | -51.8% | -54.2% | -37.8% | -48.5% | -39.9% | -55.1% | -48.4% | -56.0% | -57.1% | -60.2% |
| ROA | -35.9% | -35.9% | -39.3% | -26.6% | -34.6% | -27.5% | -37.5% | -38.1% | -41.8% | -42.9% | -41.1% |
| ROIC | -36.5% | -36.5% | -39.5% | -29.7% | -38.8% | -33.4% | -39.5% | -96.4% | — | -1037.6% | — |
| ROCE | -43.1% | -43.1% | -48.4% | -36.0% | -43.1% | -31.5% | -31.6% | -43.8% | -47.9% | -48.4% | -47.6% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.38 | 0.38 | 0.27 | 0.28 | 0.23 | 0.17 | 0.25 | 0.11 | 0.09 | 0.19 | 0.15 |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | 0.15 | 0.15 | 0.17 | 0.10 | -0.03 | -0.18 | -0.30 | -1.09 | -0.96 | -1.07 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | — | — | — | — | — | — | — | -55.02 | -38.27 | -32.87 | -19.44 |
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 5.79 | 5.79 | 7.58 | 8.48 | 4.40 | 7.79 | 5.78 | 8.17 | 7.53 | 9.29 | 6.14 |
| Quick Ratio | 5.79 | 5.79 | 7.58 | 8.48 | 4.40 | 7.79 | 5.78 | 8.17 | 7.53 | 9.29 | 6.14 |
| Cash Ratio | 5.65 | 5.65 | 7.24 | 8.06 | 3.82 | 7.58 | 5.64 | 7.96 | 7.37 | 9.14 | 6.07 |
| Asset Turnover | — | 0.02 | 0.03 | 0.13 | 0.14 | 0.06 | 0.05 | 0.04 | 0.02 | 0.04 | 0.05 |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | 50.31 | 94.76 | 10.49 | 145.85 | 56.70 | 64.04 | — | 38.50 | — | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $119M | $114M | $98M | $97M | $95M | $82M | $68M | $56M | $42M | $32M |
Includes 30+ ratios · 15 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying FATE stock.
Fate Therapeutics, Inc.'s current P/E ratio is -1.0x. This places it at the 50th percentile of its historical range.
Fate Therapeutics, Inc.'s return on equity (ROE) is -51.8%. The historical average is -54.3%.
Based on historical data, Fate Therapeutics, Inc. is trading at a P/E of -1.0x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Fate Therapeutics, Inc. has -94.1% gross margin and -2222.4% operating margin.
Key Metrics
Top Statement Risk
Cash runway depletion absent pipeline catalyst
Metrics are mathematically derived from official filings.
P/S Multiple Distorted by Collapsing Revenue Base
FATE's price-to-sales ratio of 36.3x reflects a collapsing revenue denominator rather than robust commercial traction, as quarterly revenue has contracted ~69% from $6.8M in 2024Q2 to $2.1M in 2026Q2 per the company's reported financial statements.
The 36.3x P/S multiple places FATE in an unusual category where the ratio signals extreme valuation on paper, but the underlying issue is that collaboration-based revenue is lumpy and unsustainable rather than reflective of a scalable commercial franchise. The forward P/E and EV/EBITDA are both unavailable, meaning the market is pricing FATE entirely on pipeline optionality and cash burn trajectory rather than any earnings-based framework. At a P/B of 1.19x — the lowest among the five gene-editing peers (range 1.19x to 8.46x) — the market appears to be discounting FATE's book value more severely than competitors, which may reflect the faster pace of equity erosion (64% decline over ten quarters) relative to peers.
Negative Operating Margins Signal Structural Loss-Making Model
Operating margins have remained negative across all ten reported quarters, ranging from -6.7% in 2024Q2 to -33.2% in 2024Q4, with the latest quarter at -15.0%, indicating that FATE's cost structure cannot be covered by its current revenue base per the company's quarterly income statements.
The gross margin oscillation between -124.6% and 100.0% renders it analytically meaningless, confirming that milestone-based revenue recognition is not synchronized with manufacturing cost incurrence — a structural distortion that prevents any meaningful assessment of unit economics. Net margin of -14.5% in 2026Q2 represents a modest improvement from the -28.0% trough in 2024Q4, but this improvement is attributable to aggressive cost cuts (SG&A down ~72%, R&D down ~30% per prior analysis) rather than any revenue inflection. The true earning power metric for FATE is currently its quarterly cash burn relative to cash reserves: at approximately $23.5M in quarterly free cash outflow against $32.4M in cash, the company is generating no economic profit and the margin trajectory offers no evidence of a path to breakeven.
Negative ROIC Reflects Pure Capital Consumption Phase
ROIC has been consistently negative across all ten quarters, ranging from -7.8% in 2024Q2 to -11.7% in 2024Q4 with 2026Q2 at -11.3%, confirming that every dollar of invested capital is being consumed rather than compounded according to FATE's reported financial statements.
An asset turnover ratio oscillating between 0.00 and 0.01 — essentially zero — indicates that FATE's asset base generates virtually no revenue, which is consistent with a pre-commercial biotech that has outsourced manufacturing and holds cash and intellectual property rather than revenue-generating operating assets. ROE of -18.1% in 2026Q2 is less negative than the -24.4% peer average for CRISPR Therapeutics and far better than NTLA's -57.8%, but this reflects a smaller equity base (down 64%) rather than improving returns, meaning the ratio is being mechanically compressed by denominator erosion. For FATE, return on invested capital is not a meaningful performance metric until the company demonstrates that its pipeline assets can generate returns exceeding its cost of capital; at present, the ROIC trend signals ongoing capital destruction with no visible inflection point.
Debt-to-Equity Doubling Driven by Equity Erosion
FATE's debt-to-equity ratio has doubled from 0.24 in 2024Q1 to 0.49 in 2026Q2 despite total debt declining modestly from $102.1M to $75.7M, because shareholders' equity has contracted 64% from $426.1M to $153.4M per the company's reported balance sheets.
The leverage increase is entirely denominator-driven — FATE has been retiring debt in absolute terms while losses deplete equity at a far faster rate, meaning the rising D/E ratio reflects balance sheet deterioration rather than incremental borrowing. With interest coverage data unavailable in the reported quarterly metrics, the sustainability of the $75.7M debt load cannot be assessed from the ratio table alone, though the prior cash flow analysis indicates that quarterly free cash outflows of ~$23.5M could strain debt service if the cash balance continues to decline from $32.4M. Compared to the peer group, FATE's 0.49x D/E sits above NTLA (0.14x) and CRSP (0.21x) but below SANA (0.49x, equivalent) and far below EDIT (2.81x); the concern is not the absolute leverage level but the trajectory, which investors should monitor as equity continues to erode.
Current Ratio Decline Masks Critical Cash Runway Risk
The current ratio has declined from 9.18x in 2024Q2 to 4.85x in 2026Q2 — a 47% reduction — while cash reserves have fallen to $32.4M against roughly $23.5M in quarterly free cash outflow, suggesting a runway of only a few months based on FATE's reported balance sheets.
The current and quick ratios are identical at 4.85x across all reported periods, confirming that FATE holds no inventory — consistent with its outsourced manufacturing model — and that all current assets are cash or cash equivalents, making the liquidity picture entirely dependent on cash burn trajectory rather than working capital management. While a 4.85x current ratio would signal robust liquidity for an operating company, for FATE it represents a finite and rapidly depleting resource; at the current burn rate, the ratio would approach 1.0x within approximately four quarters absent new financing. Under severe stress — such as a failed clinical readout or delayed partnership milestone — the absence of deferred revenue (which fell to zero in 2026Q2) and the lack of a revolving credit facility in the disclosed data suggest limited alternatives to equity dilution for extending the runway.
P/S Is the Most Misapplied Ratio for FATE
The price-to-sales ratio of 36.3x is the most commonly misapplied metric for FATE because the company's revenue is derived from lumpy, non-recurring collaboration milestones rather than a scalable commercial product, making the ratio mathematically valid but analytically meaningless according to FATE's reported financial statements.
A 36.3x P/S would normally signal extreme overvaluation for an operating business, but applying it to FATE obscures the real analytical question: how long the remaining cash balance can fund pipeline development before a financing event becomes necessary. The more relevant ratios for this business model are cash burn rate relative to cash reserves (approximately $23.5M quarterly burn against $32.4M in cash) and equity erosion trajectory (64% decline over ten quarters), which together frame the actual risk-reward calculus far more accurately than any sales-based multiple. Investors relying on P/S comparisons across the gene-editing peer group — where CRSP trades at a lower market cap of $5.0B with materially larger cash reserves and late-stage clinical assets — would draw incorrect conclusions about relative value; the appropriate alternative metric for FATE is a cash runway analysis supplemented by pipeline stage-weighted optionality valuation.